Latest News for: aad

Edit

Major IMF praise for AADE

Ekathimerini 24 Apr 2026
The operation of the Independent Authority for Public Revenue (AADE) stands out as a turning point for the modernization of the state, at a time when Greece is steadily seeking more effective and transparent institutions.
Edit

Dr. Reju-All Debuts Pharmacist-Led Skincare Approach at AAD 2026, Engaging Nearly 5,000 Industry Professionals

PR Newswire 23 Apr 2026
Reju-All, a K-pharmacy skincare brand rooted in ingredient-driven formulation, debuted its pharmacist-led approach at the American Academy of Dermatology (AAD) Annual Meeting 2026 ... Reju-All, walks guests through the brand's product lineup at AAD 2026.
Edit

CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 (Clinuvel Pharmaceuticals Limited)

Public Technologies 15 Apr 2026
Building on momentum from the 2025 AAD meeting, AAD 2026 saw ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues.
Edit

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

PR Newswire 01 Apr 2026
... Meeting (AAD 2026) in Denver, Colorado. The AAD 2026 clinical poster of BBT001 titled, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody.
Edit

LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026

Business Wire 31 Mar 2026
... the TRACE study of tralokinumab, at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
Edit

Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)

PR Newswire 30 Mar 2026
"Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients' aesthetic concerns." ... A complete list of e-posters presented at AAD are below.
Edit

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 ...

Rutland Herald 29 Mar 2026
ZUG, Switzerland--(BUSINESS WIRE)--Mar 28, 2026-- ....
Edit

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) ...

The Ridgway Record 29 Mar 2026
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study ....
Edit

Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting

Bennington Banner 28 Mar 2026
Data presentations underscore category leadership and expertise in dermatology and immunology ....
Edit

UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete ...

Auburnpub dot com 28 Mar 2026
Post hoc analyses of BIMZELX (bimekizumab-bkzx) using the ...
Edit

UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years ...

Fairbanks Daily News-Miner 28 Mar 2026
Symptom control throughout three years ... Of those .
Edit

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented ...

Nasdaq Globe Newswire 28 Mar 2026
AAD. new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session ... .
Edit

AAD 2026: Incyte Presentation (Incyte Corporation)

Public Technologies 28 Mar 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 130529347) .
Edit

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

News-Press Now 28 Mar 2026
One-year Phase 3 data for ICOTYDE to ...
Edit

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

PR Newswire 28 Mar 2026
These results were presented in a late-breaking presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting and simultaneously published in Arthritis & Rheumatology.  ...   ... TOGETHER-PsA 36-Week Results ... −0.44 ... 4.8.

Article Search

tools
×
×
×
×